jin jin yan - Search Results

Year	Number of Results
2008	3
2011	1
2013	1
2014	4
2015	5
2016	1
2017	4
2019	3
2020	5
2021	1
2022	1
2024	0

1

Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.

Zhu R, Lu D, Chu YW, Chai A, Green M, Zhang N, Jin JY. Zhu R, et al. Among authors: jin jy. AAPS J. 2017 May;19(3):669-681. doi: 10.1208/s12248-017-0056-x. Epub 2017 Feb 21. AAPS J. 2017. PMID: 28224402 Review.

2

Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs.

Liu G, Lu J, Lim HS, Jin JY, Lu D. Liu G, et al. Among authors: jin jy. CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1614-1627. doi: 10.1002/psp4.12871. Epub 2022 Oct 20. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 36193885 Free PMC article.

3

Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.

Chen Y, Ma F, Jones NS, Yoshida K, Chiang PC, Durk MR, Wright MR, Jin JY, Chinn LW. Chen Y, et al. Among authors: jin jy. CPT Pharmacometrics Syst Pharmacol. 2020 Jun;9(6):332-341. doi: 10.1002/psp4.12515. Epub 2020 May 29. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32383787 Free PMC article.

4

Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.

Lu D, Lu T, Gibiansky L, Li X, Li C, Agarwal P, Shemesh CS, Shi R, Dere RC, Hirata J, Miles D, Chanu P, Girish S, Jin JY. Lu D, et al. Among authors: jin jy. CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):48-59. doi: 10.1002/psp4.12482. Epub 2019 Dec 23. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 31749251 Free PMC article.

5

Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.

Zhu R, Poland B, Wada R, Liu Q, Musib L, Maslyar D, Cho E, Yu W, Ma H, Jin JY, Budha N. Zhu R, et al. Among authors: jin jy. CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):240-248. doi: 10.1002/psp4.12394. Epub 2019 Mar 6. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 30762302 Free PMC article.

6

Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.

Lu T, Gibiansky L, Li X, Li C, Shi R, Agarwal P, Hirata J, Miles D, Chanu P, Girish S, Jin JY, Lu D. Lu T, et al. Among authors: jin jy. Leuk Lymphoma. 2020 Dec;61(12):2905-2914. doi: 10.1080/10428194.2020.1795154. Epub 2020 Jul 24. Leuk Lymphoma. 2020. PMID: 32705923

7

Complete mitochondrial genome of Brachionus rubens from wuhu, China (Rotifera, Brachionidae).

Zhang Y, Zhang HY, Yan JJ, Xia MN, Liu YL, Lu YM, Yan YZ, Cheng SH. Zhang Y, et al. Among authors: yan jj. Mitochondrial DNA B Resour. 2021 Mar 26;6(3):1194-1196. doi: 10.1080/23802359.2021.1903351. Mitochondrial DNA B Resour. 2021. PMID: 33829085 Free PMC article.

8

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.

Lu D, Jin JY, Girish S, Agarwal P, Li D, Prabhu S, Dere RC, Saad OM, Nazzal D, Koppada N, Ramanujan S, Ng CM. Lu D, et al. Among authors: jin jy. Pharm Res. 2015 Jun;32(6):1907-19. doi: 10.1007/s11095-014-1585-y. Epub 2014 Dec 3. Pharm Res. 2015. PMID: 25467958 Free PMC article.

9

Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.

Lu D, Li C, Riggs M, Polhamus D, French J, Agarwal P, Chen SC, Vadhavkar S, Patre M, Strasak A, Quartino A, Jin JY, Girish S. Lu D, et al. Among authors: jin jy. Cancer Chemother Pharmacol. 2019 Jul;84(1):175-185. doi: 10.1007/s00280-019-03852-z. Epub 2019 May 17. Cancer Chemother Pharmacol. 2019. PMID: 31102024 Clinical Trial.

10

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Shi R, et al. Among authors: jin jy. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. Cancer Chemother Pharmacol. 2020. PMID: 32770353 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year